• English
    • Norsk
  • English 
    • English
    • Norsk
  • Administration
View Item 
  •   Home
  • Øvrige samlinger
  • Høstingsarkiver
  • CRIStin høstingsarkiv
  • View Item
  •   Home
  • Øvrige samlinger
  • Høstingsarkiver
  • CRIStin høstingsarkiv
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: A prospective study

Cai, Tommaso; Tamanini, Irene; Cocci, Andrea; di Maida, Fabrizio; Caciagli, Patrizio; Migno, Serena; Mereu, Liliana; Tateo, Saverio; Malossini, Gianni; Palmieri, Alessandro; Verze, Paolo; Mirone, Vincenzo; Johansen, Truls Erik Bjerklund
Journal article; AcceptedVersion; Peer reviewed
View/Open
Xyloglucan%2C+h ... Is+a+prospective+study.pdf (783.5Kb)
Year
2019
Permanent link
http://urn.nb.no/URN:NBN:no-81008

CRIStin
1751381

Metadata
Show metadata
Appears in the following Collection
  • Institutt for klinisk medisin [5823]
  • CRIStin høstingsarkiv [16845]
Original version
Future Microbiology. 2019, 14 (12), 1013-1021, DOI: https://doi.org/10.2217/fmb-2019-0145
Abstract
Aim: To evaluate the efficacy of a medical device containing xyloglucan, hibiscus and propolis in the management of recurrent urinary tract infections (rUTIs). Patients & methods: Sixty-one women affected by rUTIs received this medical device, one capsule a day for 15 days (one cycle every month, for 6 months), in an observational, prospective study. Clinical and microbiological evaluations were performed at baseline and 1, 3 and 6 months from enrolment. Results: At first follow-up, 41 reported a clinical improvement and a return to their clinical status before UTI, while 47 and 51 did so at the second and third follow-up evaluations. A statistically significant clinical improvement was reported at each follow-up visit (quality of life [QoL] 94.2 vs 98.6; QoL 94.1 vs 98.7; QoL 94.2 vs 99.1; p < 0.001). A statistically significant reduction in antibiotic use was reported. Conclusion: This medical device is able to improve quality of life in women with rUTIs, reduce recurrences and antibiotic use.
 
Responsible for this website 
University of Oslo Library


Contact Us 
duo-hjelp@ub.uio.no


Privacy policy
 

 

For students / employeesSubmit master thesisAccess to restricted material

Browse

All of DUOCommunities & CollectionsBy Issue DateAuthorsTitlesThis CollectionBy Issue DateAuthorsTitles

For library staff

Login
RSS Feeds
 
Responsible for this website 
University of Oslo Library


Contact Us 
duo-hjelp@ub.uio.no


Privacy policy